These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12161038)

  • 1. Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases.
    Garcia-Monco JC; Coleman JL; Benach JL
    J Neuroimmunol; 2002 Aug; 129(1-2):216-23. PubMed ID: 12161038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
    Cinque P; Nebuloni M; Santovito ML; Price RW; Gisslen M; Hagberg L; Bestetti A; Vago G; Lazzarin A; Blasi F; Sidenius N
    Ann Neurol; 2004 May; 55(5):687-94. PubMed ID: 15122709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of the urokinase plasminogen activator system in patients with bacterial meningitis.
    Winkler F; Kastenbauer S; Koedel U; Pfister HW
    Neurology; 2002 Nov; 59(9):1350-5. PubMed ID: 12427882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
    Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
    Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome.
    Ostergaard C; Benfield T; Lundgren JD; Eugen-Olsen J
    Scand J Infect Dis; 2004; 36(1):14-9. PubMed ID: 15000553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease.
    Sidenius N; Nebuloni M; Sala S; Zerbi P; Price RW; Gisslen M; Hagberg L; Vago L; Lazzarin A; Blasi F; Cinque P
    J Neuroimmunol; 2004 Dec; 157(1-2):133-9. PubMed ID: 15579290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A soluble form of the urokinase plasminogen activator receptor (suPAR) can bind to hematopoietic cells.
    Mizukami IF; Todd RF
    J Leukoc Biol; 1998 Aug; 64(2):203-13. PubMed ID: 9715260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
    Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
    Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients.
    McCabe NP; Angwafo FF; Zaher A; Selman SH; Kouinche A; Jankun J
    Oncol Rep; 2000; 7(4):879-82. PubMed ID: 10854562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
    Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
    Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization.
    Selleri C; Montuori N; Ricci P; Visconte V; Carriero MV; Sidenius N; Serio B; Blasi F; Rotoli B; Rossi G; Ragno P
    Blood; 2005 Mar; 105(5):2198-205. PubMed ID: 15494432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.
    Sidenius N; Sier CF; Ullum H; Pedersen BK; Lepri AC; Blasi F; Eugen-Olsen J
    Blood; 2000 Dec; 96(13):4091-5. PubMed ID: 11110678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients.
    Gao W; Wang Z; Bai X; Xi X; Ruan C
    Thromb Res; 2001 Apr; 102(1):25-31. PubMed ID: 11323011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
    Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
    J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
    Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
    Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. suPAR, a soluble form of urokinase plasminogen activator receptor, inhibits human prostate cancer cell growth and invasion.
    Piccolella M; Festuccia C; Millimaggi D; Locatelli A; Bologna M; Motta M; Dondi D
    Int J Oncol; 2008 Jan; 32(1):185-91. PubMed ID: 18097558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis.
    Slot O; Brünner N; Locht H; Oxholm P; Stephens RW
    Ann Rheum Dis; 1999 Aug; 58(8):488-92. PubMed ID: 10419867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.